Bim and Bmf in tissue homeostasis and malignant disease.

PiГ±on JD, Labi V, Egle A, Villunger A. Oncogene. 2008 Dec,27 Suppl 1:S41-52. doi: 10.1038/onc.2009.42.

A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.

Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M, Alon R. J Leukoc Biol. 2008 Oct,84(4):1130-40. doi: 10.1189/jlb.0208088. Epub 2008 Jul 24.

IMMUNOMODULATORY CAPACITY OF MYELOMA-DERIVED CHEMOKINE CCL27

Johrer, K, Olivier, A, Unger, M, Maizner, E, Neureiter, D, Greil, R ANTICANCER RES. 2008, 28(5C): 3336-3337.

Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12

Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Poestlberger, S, Menzel, C, Jakesz, R, Kubista, E, Marth, C, Greil, R J CLIN ONCOL. 2008, 26(15):

The Austrian Fulvestrant Registry: Results from a prospective observation of fulvestrant in postmenopausal patients

Bartsch, R, Mlineritsch, B, Gnant, M, Niernberger, T, Pluschnig, U, Greil, R, Pober, M, Sevelda, P, Thaler, J, Steger, GG J CLIN ONCOL. 2008, 26(15):

R-CHOP plus thalidomide for previously untreated mantle cell lymphoma

Drach, J, Hopfinger, G, Fridrik, M, Greil, R, Thaler, J, Keil, F, Lang, A, Jaeger, U, Raderer, M ANN ONCOL. 2008, 19: 214-215.

The Dark Side of the Moon – the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.

Greil R. Breast Care (Basel). 2009,4(3):144-147. Epub 2009 Jun 26.

FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY

Egle, A, Melchardt, T, Pleyer, L, Tinhofer, I, Lang, A, Keil, F, Thaler, J, Gunsilius, E, Fridrik, M, Greil, R HAEMATOL-HEMATOL J. 2009, 94: 140-140.

The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia

Weiss, L, Melchardt, T, Grabmer, C, Egle, A, Tinhofer, I, Greil, R BLOOD. 2009, 114(22): 510-510.

The REVLIRIT CLL5 AGMT Study – a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis

Egle, A, Steurer, M, Melchardt, T, Stoll, M, Greil, R BLOOD. 2009, 114(22): 1341-1342.